Patent intelligence · US
US 7622610
Crystalline ACAT inhibitor
Crystalline ACAT inhibitor
Patent details — US 7622610
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 24, 2009
- Expiration
- Nov 19, 2029
- Applicant
- Graceway Pharmaceuticals. LLC
- Claims
- 10
- CPC classes
- A61K, A61K31/16, A61P, A61P17/00
Quick answer
US 7622610 (Crystalline ACAT inhibitor) is held by Graceway Pharmaceuticals. LLC. Status: granted. Granted Nov 24, 2009. Expires Nov 19, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Graceway Pharmaceuticals. LLC
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/16, A61P, A61P17/00, A61P17/08, A61P17/10
More from Graceway Pharmaceuticals. LLC
Related pharmaceutical patents in our USPTO index.
-
US 12414943
Nimodipine parenteral administration
granted -
US 12049487
Universal chimeric antigen receptor T-cell preparation technique
granted -
US 11840575
Engineered immune cells targeting BCMA and their uses thereof
granted -
US 11484501
Mechanochemical activated dry amorphisation by milling equilibrium between ap mesoporous silica
granted -
US 11478424
Mechanochemcial activated dry amorphisation by milling equilibrium between AP mesoporous silica
granted -
US 11478420
Vaginal probiotic products and related processes
granted -
US 11291672
Betamethasone oral spray formulation and method of use to treat ataxia
granted -
US 11052029
Cation compatible metal oxides and oral care compositions containing the metal oxides
granted
Frequently asked questions
What is US patent 7622610?
US 7622610 (Crystalline ACAT inhibitor) is held by Graceway Pharmaceuticals. LLC. Status: granted. Granted Nov 24, 2009. Expires Nov 19, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7622610?
Graceway Pharmaceuticals. LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.
When does US 7622610 expire?
Our index shows an expiration date of Nov 19, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.